In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. Solifenacin 10 mg also decreased the frequency of nocturia. Solifenacin therapy was associated with a favorable tolerability profile and a low incidence of dry mouth, especially at the 5 mg starting dose.
This prospective, controlled study was undertaken to evaluate the early urodynamic and symptomatic impact of the lipido-sterolic extract of Serenoa repens (Permixon 1 1 ) in the treatment of patients with benign prostatic hyperplasia (BPH).A total of 75 patients, aged 52 ± 78 y with lower urinary tract symptoms due to mild/moderate BPH (mean International Prostate Symptom Score (I-PSS) 8.2) were included in the study, of which 57 received Permixon 1 1 160 mg twice daily for 9 weeks. Urodynamic evaluation, including maximum urinary¯ow rate (Q max ) and detrusor pressure (DP), was performed at baseline and endpoint. Prostate volume and post-void residual urine volume were assessed by transrectal and transabdominal ultrasound respectively. In addition, the I-PSS and its associated quality of life (QoL) score were determined and adverse events were recorded.Baseline parameters were comparable between the active treatment and control groups. After 9 weeks of Permixon 1 1 treatment Q max increased (6.0%, P`0.001), and there were reductions in DP at maximum¯ow (12.8%, P`0.001), opening DP (12.6%, P`0.001), and residual urine volume (12.6%, P`0.05). In addition, the I-PSS and QoL score both decreased signi®cantly from baseline in the active treatment group (26.8% and 18.2% respectively, P`0.001). None of these parameters improved signi®cantly in control patients. There were also improvements in prostate volume (2.7%) and maximum DP (5.2%) in the Permixon 1 1 group which did not reach signi®cance. Three patients receiving Permixon 1 1 experienced gastrointestinal disturbances but these did not lead to withdrawal or require additional therapy.In patients with mild/moderate BPH, Permixon 1 1 treatment reduced infravesical obstruction and produced a rapid improvement in urodynamic parameters and symptoms. The drug was well tolerated. These data support the use of Permixon 1 1 as ®rst-line therapy in patients with uncomplicated symptomatic BPH. Prostate Cancer and Prostatic Diseases (2000) 3, 195±199.
A concept of the front-end system of the XCELS (eXawatt Center for Extreme Light Studies) facility is presented. Its design is aimed at achieving high stability of laser radiation parameters and possibility of their control in a wide range. Optically synchronised chirped signal (wavelength 910 nm, bandwidth more than 100 nm, and duration ∼3 ns) and pump (wavelength 1054 nm, bandwidth ∼1 nm, and duration ∼4 ns) pulses for XCELS parametric amplifiers will be implemented at the output of the front-end system. Chirped femtosecond pulses with energies above 100 mJ [no more than 15 fs long after compression, with carrier-envelope phase (CEP) stabilisation] will have a repetition rate up to 100 Hz, which will allow one to implement active energy stabilisation and to minimise the angular jitter of the emitted beam at the XCELS output. The application of picosecond pumping in the parametric amplifier of the front-end system should provide a high contrast of femtosecond pulses. The pump pulse will be linearly frequency-modulated; this approach will not affect the parametric amplification efficiency but make it possible to use spectral methods to control the pump pulse shape in order to form a pulse of specified shape at the output of power amplifiers, even under conditions of their strong saturation.
A new front-end laser system with optical synchronization of chirped
femtosecond and pump pulses for the petawatt laser complex PEtawatt
pARametric Laser (PEARL) has been developed. The new front-end system
provides a broader femtosecond pulse spectrum, temporal shaping of the
pump pulse, and a significant increase in the stability of the
parametric amplification stages of the PEARL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.